|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 07, 2018 ) Global Orphan Drugs Market: Industry Analysis and Outlook (2018-2022) Report provides an extensive research on the fast-evolving Orphan Drugs Market. It also gives competitive landscape of the leading companies with regional and global analysis of the market till 2022.
Orphan diseases are typically life-threatening or chronically debilitating for which no or inadequate alternative treatments are available. An orphan disease refers to any rare disease which affects a smaller share of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.
Get Sample PDF of the Report @ http://www.orbisresearch.com/contacts/request-sample/2274237
The report profiles key players of the market including –
• Roche holding AF
• Novartis International AG
• Bristol-Myers Squibb
• Celgene Corporation.
Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.
Orphan drug market is likely to witness a growth in future with increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The US and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan drug designations. Asia is likely to experience further growth with increasing orphan designations in Japan and improving healthcare facilities.
The report discusses the major growth drivers and challenges of the market, covering the
• US
• Europe
• Asia
The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends & development of this market include rise in orphan drug approvals, accelerating pipeline sales of orphan drugs, development of drug therapies and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.
Request to Enquire before buying the Report @ http://www.orbisresearch.com/contacts/enquiry-before-buying/2274237
Table of Content:
1. Overview
1.1 Orphan Disease
1.2 Orphan Drugs
2. Global Orphan Drugs Market
2.1 Global Orphan Drugs Market by Value
2.2 Global Orphan Drugs Market Forecast by Value
2.3 Global Orphan Drugs Market by Product
2.3.1 Global Revlimid Drug Revenue Forecast
2.3.2 Global Rituxan Drug Revenue Forecast
2.3.3 Global Opvido Drug Revenue Forecast
2.4 Global Orphan Drugs Market by Therapy
2.4.1 Global Oncology Therapy Market Forecast by Value
2.4.2 Global Blood Therapy Market Forecast by Value
2.4.3 Global Central Nervous System Therapy Market Forecast by Value
3. Regional Market Analysis
3.1 The Americas
3.1.1 The US Orphan Drugs Spending Forecast
3.1.2 The US Orphan Drug by Designation Volume
3.1.3 The US Orphan Drug Average & Median Cost per Patient
3.1.4 The US Orphan Drug Average & Median Cost per Patient Forecast
3.1.5 Canada Orphan Drugs Spending
3.1.6 Canada Orphan Drugs Spending Forecast
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
3.2.2 Europe Orphan Drugs Market by Product
3.2.3 Europe Orphan Drug by Designation Volume
3.3 Asia
3.3.1 Japan Orphan Drug by Designation Volume
3.3.2 India Orphan Drugs Market Forecast by Value
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Attractive Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
4.1.5 Improving Economic Condition
4.1.6 Increasing Prevalence of Chronic Diseases
4.2 Key Trends & Development
4.2.1 Rise in Orphan Drug Approvals
4.2.2 Accelerating Pipeline Sales of Orphan Drugs
4.2.3 Development of Drug Therapies
4.2.4 Increasing Scope of Gene Therapy
4.3 Challenges
4.3.1 High Costs
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Global Orphan Drugs Market Share by Company
5.1.3 Global Oncology Orphan Drugs Market Share by Company
5.2 The US
5.2.1 The US Top 10 Orphan Drugs Sales by Company
5.3 Europe
5.3.1 Europe Orphan Drugs Market Share by Company
6. Company Profiles
6.1 Novartis International AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Celgene Corporation
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
